HomeInsightsStock Comparison

Gujarat Themis Biosyn Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Gujarat Themis Biosyn Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Jul 19, 2025

Key Highlights

  • The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 366.7 as of 18 Jul 15:30.
  • The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 38.1 on March 2025 . This represents a CAGR of 9.18% over 6 years.
  • The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 416392 crore on March 2025 . This represents a CAGR of 30.45% over 6 years.
  • The revenue of Gujarat Themis Biosyn Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 13571 crore as compare to the Dec '24 revenue of ₹ 14141 crore. This represent the decline of -4.03%.
  • The ebitda of Gujarat Themis Biosyn Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 3967 crore as compare to the Dec '24 ebitda of ₹ 4158 crore. This represent the decline of -4.6%.
  • The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 2160 crore over 8 quarters. This represents a CAGR of 3.60% .
  • The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 10.12 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 89.64 % on March 2025 . This represents a CAGR of 20.09% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Gujarat Themis Biosyn Ltd

  • Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
  • It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Sun Pharmaceutical Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Gujarat Themis Biosyn Ltd News Hub

News

Board of Gujarat Themis Biosyn recommends final dividend

Gujarat Themis Biosyn announced that the Board of Directors of the Company at its meeting ...

Read more

21 May 2025 11:36

News

Gujarat Themis Biosyn to announce Quarterly Result

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 20 M...

Read more

16 May 2025 15:57

News

Gujarat Themis Biosyn to convene board meeting

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 14 F...

Read more

11 Feb 2025 10:53

News

Board approved merger of Gujarat Themis Biosyn with Themis Medicare

The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have appr...

Read more

19 Nov 2024 09:10

News

Gujarat Themis Biosyn schedules board meeting

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 O...

Read more

19 Oct 2024 09:25

News

Gujarat Themis' Q1 PAT falls over 25% YoY to Rs 13 crore

This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore. Tota...

Read more

27 Jul 2024 09:25

Sun Pharmaceutical Industries Ltd News Hub

News

Sun Pharmaceutical Industries Ltd spurts 2.56%, rises for third straight session

Sun Pharmaceutical Industries Ltd rose for a third straight session today. The stock is qu...

Read more

15 Jul 2025 13:05

News

Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp

The drug is indicated for the treatment of alopecia areata ' a condition in which the immu...

Read more

15 Jul 2025 15:41

News

Sun Pharmaceutical Industries launches LEQSELVI' (deuruxolitinib) 8 mg tablets in United States

Sun Pharmaceutical Industries announced LEQSELVI' (deuruxolitinib) 8 mg tablets is now ava...

Read more

14 Jul 2025 16:48

News

Sun Pharma settles litigation related to LEQSELVI' with Incyte

 Sun Pharmaceutical Industries  announced that further to its intimation dated 10 April 20...

Read more

14 Jul 2025 16:53

News

Sun Pharmaceuticals Industries to table results

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Compan...

Read more

12 Jul 2025 10:08

News

Sun Pharma updates on US FDA inspection

Sun Pharmaceutical Industries has informed that the US FDA conducted a Good Manufacturing ...

Read more

14 Jun 2025 12:11

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Gujarat Themis Biosyn Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Sun Pharmaceutical Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Gujarat Themis Biosyn Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 3,995 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 406,267 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Sun Pharmaceutical Industries Ltd?

As of July 19, 2025, the Gujarat Themis Biosyn Ltd stock price is INR ₹366.7. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1693.25.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions